ANTX - AN2 Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANTX is currently covered by 2 analysts with an average price target of $4.42. This is a potential upside of $3.16 (250.79%) from yesterday's end of day stock price of $1.26.

AN2 Therapeutics's activity chart (see below) currently has 25 price targets and 27 ratings on display. The stock rating distribution of ANTX is 16.67% HOLD and 83.33% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 29.17% with an average time for these price targets to be met of 69 days.

Highest price target for ANTX is $2, Lowest price target is $2, average price target is $2.

Most recent stock forecast was given by ROY BUCHANAN from JMP on 05-May-2025. First documented stock forecast 19-Apr-2022.

Best performing analysts who are covering ANTX - AN2 Therapeutics:

Kevin Degeeter Joseph Schwartz Liisa Bayko Roy Buchanan

Currently out of the existing stock ratings of ANTX, 1 are a HOLD (16.67%), 5 are a BUY (83.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$2

$0.7 (53.85%)

$5

5 months 5 days ago
(05-May-2025)

0/8 (0%)

$0.8 (66.67%)

Hold

$1

$-0.3 (-23.08%)

1 years 2 months 1 days ago
(09-Aug-2024)

1/3 (33.33%)

$-0.03 (-2.91%)

7

Hold

$2

$0.7 (53.85%)

$7

1 years 4 months 24 days ago
(16-May-2024)

1/3 (33.33%)

$-0.27 (-11.89%)

15

Buy

$27

$25.7 (1976.92%)

$24

2 years 27 days ago
(13-Sep-2023)

2/4 (50%)

$12.12 (81.45%)

254

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ANTX (AN2 Therapeutics) average time for price targets to be met?

On average it took 69 days on average for the stock forecasts to be realized with a an average price target met ratio 29.17

Which analyst has the current highest performing score on ANTX (AN2 Therapeutics) with a proven track record?

KEVIN DEGEETER

Which analyst has the current lower performing score on ANTX (AN2 Therapeutics) with a proven track record?

ROY BUCHANAN

Which analyst has the most public recommendations on ANTX (AN2 Therapeutics)?

Kevin Degeeter works at LADENBURG and has 4 price targets and 3 ratings on ANTX

Which analyst is the currently most bullish on ANTX (AN2 Therapeutics)?

Kevin Degeeter with highest potential upside - $25.7

Which analyst is the currently most reserved on ANTX (AN2 Therapeutics)?

Joseph Schwartz with lowest potential downside - -$0.3

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?